Cargando…
Intravenous Immunoglobulin may Reverse Multisystem Inflammation in COVID-19 Pneumonitis and Guillain–Barré Syndrome
INTRODUCTION: The novel coronavirus disease 2019 (COVID-19) poses an unprecedented crisis for public health, although several potential therapies have been provisionally applied but a unified consensus is yet to be achieved. CASE DESCRIPTION: A 75-year-old man, COVID-19 reverse transcription-polymer...
Autores principales: | Chakraborty, Nilanchal, Kumar, Hrishikesh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Jaypee Brothers Medical Publishers
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7775923/ https://www.ncbi.nlm.nih.gov/pubmed/33446983 http://dx.doi.org/10.5005/jp-journals-10071-23688 |
Ejemplares similares
-
Reversible posterior encephalopathy syndrome due to intravenous immunoglobulin in a child with Guillain-Barré syndrome
por: Incecik, Faruk, et al.
Publicado: (2011) -
Intravenous immunoglobulin in COVID-19 associated Guillain–Barré syndrome in pregnancy
por: Garcia, Jao Jarro, et al.
Publicado: (2021) -
Acute aseptic meningitis due to intravenous immunoglobulin therapy in Guillain–Barré syndrome
por: Jain, Rajendra Singh, et al.
Publicado: (2014) -
Give or take? Intravenous immunoglobulin or plasma exchange for Guillain-Barré syndrome
por: Hughes, Richard AC
Publicado: (2011) -
Intravenous immunoglobulins versus plasma exchange in the treatment of Guillain-Barré syndrome
por: Charra, B, et al.
Publicado: (2009)